Hemenway Trust Co LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,659 shares of the biopharmaceutical company’s stock after selling 4,014 shares during the period. Hemenway Trust Co LLC’s holdings in Gilead Sciences were worth $2,053,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the period. Macquarie Group Ltd. boosted its position in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after buying an additional 100,741 shares during the period. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the period. Northern Trust Corp boosted its position in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares during the period. Finally, Toronto Dominion Bank boosted its position in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares during the period. 77.96% of the stock is owned by institutional investors.
Several research firms have recently weighed in on GILD. Barclays reaffirmed an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Royal Bank of Canada reiterated a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a report on Friday, February 23rd. Finally, Leerink Swann reiterated a “market perform” rating and set a $80.00 target price (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $88.61.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.70 earnings per share. equities research analysts forecast that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.79%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.
In other news, insider John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the transaction, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the transaction, the executive vice president now owns 102,715 shares in the company, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 430,268 shares of company stock worth $34,074,395. 1.30% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/hemenway-trust-co-llc-sells-4014-shares-of-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.